In 2001, Wei et al. applied the first VEGF-based cancer vaccine in the form of xenogenic DNA to evaluate its anti-tumoral effect on three different tumor models and observed that humoral immune response against VEGF could inhibit primary tumor growth (27). The gene discussed is VEGFA; the disease is cancer.